Cargando…
Does Industry‐Conducted All‐Case Surveillance of Newly Approved Oncology Drugs Contribute to the Revision of Package Inserts in Japan?
In Japan, the Pharmaceuticals and Medical Devices Agency requires all‐case surveillance studies (ACSS) for many novel oncology drugs as a condition for approval. However, this is a major burden on the pharmaceutical industry and clinicians. The objective of this analysis was to investigate whether A...
Autores principales: | Suzuki, Akiyuki, Sato, Hitoshi, Sasaki, Yasutsuna |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6742944/ https://www.ncbi.nlm.nih.gov/pubmed/31062933 http://dx.doi.org/10.1111/cts.12644 |
Ejemplares similares
-
2015 Review of Newly Approved Oncologic Therapies
por: Medina, Patrick, et al.
Publicado: (2016) -
Analysis of safety specifications in risk management plan at the time of drug approval and addition of clinically significant adverse reactions in the package insert post‐approval in Japan
por: Saito, Rieko, et al.
Publicado: (2023) -
Assessment of Outcomes Associated With the Use of Newly Approved Oncology Drugs in Medicare Beneficiaries
por: Green, Angela K., et al.
Publicado: (2021) -
Investigation of the boxed warnings in package inserts of prescription medicines for medical professionals in Japan
por: Mino, Yasuaki, et al.
Publicado: (2022) -
Comparing the Dosing Period in Package Inserts of Antimicrobial Agents Between Japan and the United States
por: Nishigaki, Tetsuta, et al.
Publicado: (2023)